Welcome to our dedicated page for Synlogic SEC filings (Ticker: SYBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synlogic, Inc. (SYBX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a structured view of its governance, compensation, financing and strategic decisions. As a biopharmaceutical company focused on Synthetic Biotic therapeutics, Synlogic uses these filings to report on corporate actions that shape its operations and capital structure.
Key documents for SYBX include annual proxy statements on Schedule 14A, which describe the agenda for stockholder meetings, board composition, executive and director compensation, equity incentive plans and voting procedures. For example, the company’s 2025 definitive proxy statement outlines proposals to elect directors, approve advisory votes on executive compensation, adopt the Synlogic, Inc. 2025 Equity Incentive Plan and ratify the appointment of KPMG LLP as independent registered public accounting firm.
Current reports on Form 8-K provide timely disclosure of material events. A December 15, 2025 Form 8-K details the results of the 2025 annual meeting, including stockholder approval of the 2025 Equity Incentive Plan, voting outcomes for director elections, advisory votes on named executive officer compensation and ratification of the independent auditor. Earlier 8-K filings and related documents can also reflect significant corporate developments such as restructuring actions, strategic reviews, adoption of stockholder rights plans and other events relevant to Synlogic’s evaluation of strategic alternatives.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the most important points from lengthy documents, such as equity plan terms, changes in governance, or key risk and strategy disclosures. Users can quickly identify items related to equity compensation, stockholder voting, auditor selection and other governance matters without reading every page. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, proxy and related filings for SYBX are captured as they become available, helping investors and researchers monitor how Synlogic’s corporate and financial reporting evolves alongside its strategic decisions.
Synlogic, Inc. filed an amended shelf registration statement on Form S-3/A (ticker SYBX) containing an exhibit index listing charter amendments, bylaws, stock certificate form, indentures, warrant/unit/rights forms, legal opinions, auditor consents, a trustee eligibility statement and a filing fee table. Several certificates of amendment are dated June 15, 2023 and September 27, 2023. The filing shows signatures by company officers and directors dated August 15, 2025.
Synlogic, Inc. (SYBX) filed a shelf registration on Form S-3 to offer up to $150,000,000 of securities, including common stock, preferred stock, debt and warrants. The company reported that it discontinued Synpheny-3, the pivotal Phase 3 study of its lead candidate labafenogene marselecobac (SYNB1934), in February 2024 after an internal review indicated the trial was unlikely to meet its primary endpoint, and stated the decision was not based on safety or tolerability concerns.
Management says its strategy now prioritizes strategic alternatives to enhance stockholder value, including a potential merger or sale, while earlier-stage programs remain in development, notably SYNB1353 which achieved proof of mechanism in a Phase 1 study. The prospectus notes the common stock trades on Nasdaq under SYBX, with 11,698,919 shares outstanding as of August 6, 2025 and a last reported sale price of $1.39 on August 7, 2025.